Boron-containing delocalised lipophilic cations for the selective targeting of cancer cells

Article English OPEN
Calabrese, Gianpiero ; Daou, Anis ; Rova, Aikaterini ; Tseligka, Eirini D. ; Vizirianakis, Ioannis S ; Fatouros, Dimitris ; Tsibouklis, John (2017)
  • Publisher: RSC Publishing
  • Journal: MedChemComm (issn: 2040-2503, vol: 8, pp: 67-72)
  • Related identifiers: pmc: PMC6072302, doi: 10.1039/C6MD00383D
  • Subject: chemistry | /dk/atira/pure/core/subjects/pharmacy | pharmacy | biological | cancer

To limit the incidence of relapse, cancer treatments must not promote the emergence of drug resistance in tumour and cancer stem cells. Under the proviso that a therapeutic amount of boron is selectively delivered to cancer cells, Boron Neutron Capture Therapy (BNCT) may represent one approach that meets this requirement. To this end, we report on the synthesis and pharmacology of several chemical entities, based on boron-rich carborane moieties that are functionalised with Delocalized Lipophilic Cations (DLCs), which target selectively the mitochondria of tumour cells. The treatment of tumour and cancer stem cells (CSCs) with such DLC-functionalized carboranes (DLC-carboranes) induces cell growth arrest that is both highly cancer-cell selective and permanent. Experiments involving cultures of normal and cancer cells show that only normal cells exhibit recapitulation of their proliferation potential upon removal of the DLC-carborane treatment. At the molecular level, the pharmacological effect of DLC-carboranes is exerted through activation of the p53/p21 axis.
  • References (51)
    51 references, page 1 of 6

    1 Q. T. Ostrom, H. Gittleman, P. M. de Blank, J. L. Finlay, J. G. Gurney, R. McKean-Cowdin, D. S. Stearns, J. E. Wolff, M. Liu, Y. Wolinsky, C. Kruchko and J. S. Barnholtz-Sloan, Neuro-Oncology, 2016, 18(suppl 1), i1-i50.

    2 J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent, S. Rosso, J. W. W. Coebergh, H. Comber, D. Forman and F. Bray, Eur. J. Cancer, 2013, 49(6), 1374-1403.

    3 O. Visser, E. Ardanaz, L. Botta, M. Sant, A. Tavilla and P. Minicozzi, Eur. J. Cancer, 2015, 51, 2231-2241.

    4 J. S. Modica-Napolitano and K. K. Singh, Mitochondrion, 2004, 4(5-6), 755-762.

    5 Treating a malignant brain tumour (2015), Available: http:// www.nhs.uk/Conditions/brain-tumour-malignant/Pages/ Treatment.aspx, [Last accessed 28 September 2015].

    6 P. A. Sotiropoulou, M. S. Christodoulou, A. Silvani, C. Herold-Mende and D. Passarella, Drug Discovery Today, 2014, 19, 1547-1562.

    7 C. Alifieris and D. T. Trafalis, Pharmacol. Ther., 2015, 152, 63-82.

    8 J. D. Lathia, S. C. Mack, E. E. Mulkearns-Hubert, C. L. Valentim and J. N. Rich, Genes Dev., 2015, 29, 1203-1217.

    9 T. Sun, Y. Li, Y. Huang, Z. Zhang, W. Yang, Z. Du and Y. Zhou, Oncotarget, 2016, 7(28), 43095-43108.

    10 E. D. Tseligka, A. Rova, E. P. Amanatiadou, G. Calabrese, J. Tsibouklis, D. G. Fatouros and I. S. Vizirianakis, Pharm. Res., 2016, 33(8), 1945-1958.

  • Similar Research Results (1)
  • Metrics
    No metrics available
Share - Bookmark